.Pharmacolibrary.Drugs.ATC.C.C10AA02

Information

Lovastatin is an HMG-CoA reductase inhibitor (statin) used to lower cholesterol and reduce cardiovascular risk. It is approved for the treatment of primary hypercholesterolemia and mixed dyslipidemia.

Pharmacokinetics

Pharmacokinetic parameters in healthy adult volunteers after single oral dose administration.

References

1. Yin, OQ, et al., & Tomlinson, B (2012). Impact of CYP2D6 polymorphisms on the pharmacokinetics of lovastatin in Chinese subjects. European journal of clinical pharmacology 68(6) 943–949. DOI:10.1007/s00228-011-1202-5 PUBMED:https://pubmed.ncbi.nlm.nih.gov/22281720

2. Choi, DH, et al., & Choi, JS (2010). Pharmacokinetic interaction between oral lovastatin and verapamil in healthy subjects: role of P-glycoprotein inhibition by lovastatin. European journal of clinical pharmacology 66(3) 285–290. DOI:10.1007/s00228-009-0757-x PUBMED:https://pubmed.ncbi.nlm.nih.gov/20012601

3. Hurren, KM, & Pinelli, NR (2012). Drug-drug interactions with glucagon-like peptide-1 receptor agonists. The Annals of pharmacotherapy 46(5) 710–717. DOI:10.1345/aph.1Q583 PUBMED:https://pubmed.ncbi.nlm.nih.gov/22510669

Revisions

• 06/2025 initial generated model